Watchful waiting in benign prostatic hyperplasia

Current Opinion in Urology

Volumn 19, Issue 1, 2009, Pages 3-6

  Wiygul, Jeremy ^a,b   Babayan, Richard K ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY   (United States)

Author keywords

Alpha blockers; Benign prostatic hyperplasia; Transurethral resection of the prostate; Watchful waiting

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; PLACEBO;

DISEASE COURSE; HUMAN; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; RISK FACTOR; SCORING SYSTEM; SURGICAL RISK; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; WATCHFUL WAITING;

ADRENERGIC ALPHA-ANTAGONISTS; DISEASE PROGRESSION; HUMANS; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; QUINAZOLINES; TRANSURETHRAL RESECTION OF PROSTATE;

EID: 58149229463     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32831a6ec6     Document Type: Review

References (12)

1. Mebust WK, Holtgrewe HL, Cockett ATK, et al. Immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3885 patients. J Urol 1989; 141:243.
2. Arrighi HM, Metter EJ, Guess HA, et al. Natural nistory of benign prostatic hyperplasia and risk of prostatectomy. Urology 1991; 38:4-8.
3. Jacobsen SJ, Jacobsen DJ, Girman CJ, et al. Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. J Urol 1999; 162:1301-1306.
4. Wasson JH, Reda DJ, Bruskewitz RC, et al. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med 1995; 332:75-79.
5. Flanigan RC, Reda DJ, Wasson JH, et al. 5 year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs Cooperative Study. J Urol 1998; 160:12-17.
6. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia N Engl J Med 2003; 349:2387-2398.
7. Roehrborn CG, for ALTESS Study group. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. BJU Int 2006; 97:734-741.
8. Fitzpatrick JM. The natural history of benign prostatic hyperplasia. BJU Int 2006; 97 (Suppl 2):3-6 [discussion 21-22].
9. Emberton M, Fitzpatrick JM, Garcia-Losa M, et al. Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials. BJU Int 2008; 102:981-986. Epub 2008 Jun 28.
10. Emberton M. Definition of at-risk patients: dynamic variables. BJU Int 2006; (97 Suppl 2):12-15 [discussion 21-22].
11. Mochtar CA, Kiemeney LA, Laguna MP, et al. PSA velocity in conservatively managed BPH: can it predict the need for BPH-related invasive therapy? Prostate 2006; 66:1407-1412.
12. Djavan B, Fong YK, Harik M, et al. Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years. Urology 2004; 64:1144-1148.